BACARDI-LIMITED
16.9.2022 16:05:40 CEST | Business Wire | Press release
Bacardi Limited, the largest privately held spirits company in the world, today announces moves within its global marketing leadership. John Burke, Global Chief Marketing Officer of Bacardi and President of Bacardi Global Brands Limited, will retire after more than 28 years with the company at the end of 2022. During his tenure, he led many of the company’s leading brands, including most recently BACARDÍ® rum, BOMBAY SAPPHIRE® gin, MARTINI® vermouths and sparkling wines, and DEWAR’S® Blended Scotch whisky.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220916005301/en/
Ned Duggan will be promoted to Global Chief Marketing Officer of Bacardi and President of Bacardi Global Brands Limited. (Photo: Business Wire)
“John is an incredibly strategic marketer who has helped us reinvigorate many brands and keep consumer at the heart of everything that we do. He played an important role in creating a disciplined marketing organization focused on building capabilities and driving brand equity over the years,” says Mahesh Madhavan, Chief Executive Officer of Bacardi Limited. “Under his leadership, we have seen many magical moments for our brands. He leaves us having imprinted his mark in our story – and a legacy he can be very proud of.”
“I am incredibly grateful for the many opportunities I have been given in my lifetime at Bacardi. I have had the opportunity to work with and learn from some remarkable people, and I hope I have been able to help them in return. I have loved nurturing our brands to make them stronger and see them grow,” says John Burke. “I am very proud of what we have achieved together and wish Bacardi good fortune and continued success for the future.”
Following John’s retirement, Ned Duggan will be promoted to Global Chief Marketing Officer of Bacardi and President of Bacardi Global Brands Limited. Since 2017, Ned has led BACARDÍ® rum, first in market execution in North America and later globally from Bermuda as SVP. In addition to his continued leadership of BACARDÍ rum, he will add MARTINI®, DEWAR’S®, WILLIAM LAWSON’S®, D’USSÉ® Cognac, among others. Ned’s ascension is the culmination of a 17-year-tenure at Bacardi that began as an Assistant Brand Manager. His career has spanned assignments at regional and global levels working on many company brands, including DEWAR’S®, GREY GOOSE®, BOMBAY SAPPHIRE®, OXLEY®, ST-GERMAIN®, D’USSÉ®, and others. Ned, who will relocate to London, will report to CEO Mahesh Madhavan and joins the Global Leadership Team (GLT).
“I am incredibly honored and humbled to assume the role of CMO at Bacardi,” says Ned Duggan. “I have spent my career at this company, learning from the best and I am thrilled to enter this next phase of my journey working to further develop and grow our renowned portfolio.”
Kathy Parker, President & CMO of GREY GOOSE® vodka and the tequila portfolio, which includes PATRÓN® and CAZADORES®, will add BOMBAY SAPPHIRE® gin to her remit following John’s retirement. Kathy is a member of the company’s Global Leadership Team and reports to CEO Mahesh Madhavan.
About Bacardi Limited
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on Twitter, LinkedIn or Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220916005301/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
